• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Long-persisting SARS-CoV-2 spike-specific CD4+ T cells associated with mild disease and increased cytotoxicity post COVID-19

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Oct 1;16(1):8743.
doi: 10.1038/s41467-025-63711-9. Long-persisting SARS-CoV-2 spike-specific CD4[SUP]+[/SUP] T cells associated with mild disease and increased cytotoxicity post COVID-19

Guihai Liu[SUP] #[/SUP][SUP] 1 2 [/SUP], Elie Antoun[SUP] #[/SUP][SUP] 1 2 [/SUP], Anastasia Fries[SUP] 3 [/SUP], Xuan Yao[SUP] 1 2 [/SUP], Zixi Yin[SUP] 1 2 [/SUP], Danning Dong[SUP] 1 [/SUP], Wenbo Wang[SUP] 1 [/SUP], Peter A C Wing[SUP] 1 2 [/SUP], Wanwisa Dejnirattisa[SUP] 1 3 [/SUP], Piyada Supasa[SUP] 1 3 [/SUP], Chang Liu[SUP] 1 3 [/SUP], Timothy Rostron[SUP] 4 [/SUP], Craig Waugh[SUP] 5 [/SUP], Kevin Clark[SUP] 5 [/SUP], Paul Sopp[SUP] 5 [/SUP], Jeremy W Fry[SUP] 6 [/SUP], Iolanda Vendrell[SUP] 1 7 [/SUP], Jane A McKeating[SUP] 1 7 [/SUP], Juthathip Mongkolsapaya[SUP] 1 3 8 [/SUP], Gavin R Screaton[SUP] 1 3 [/SUP], Benedikt M Kessler[SUP] 1 7 [/SUP], Roman Fisher[SUP] 1 7 [/SUP], Graham Ogg[SUP] 1 9 [/SUP], Alexander J Mentzer[SUP] 1 3 [/SUP], Julian C Knight[SUP] 1 3 [/SUP], Yanchun Peng[SUP] 1 2 9 [/SUP], Tao Dong[SUP] 10 11 12 [/SUP]



Affiliations
Free article Abstract

The recent COVID-19 pandemic left behind the lingering question as whether new variants of concern might cause further waves of infection. Thus, it is important to investigate the long-term protection gained via vaccination or exposure to the SARS-CoV-2 virus. Here we compare the evolution of memory T-cell responses following primary infection with subsequent antigen exposures. Single-cell TCR analysis of three dominant SARS-CoV-2 spike-specific CD4[SUP]+[/SUP] T-cell responses identifies the dominant public TCRα clonotypes pairing with diverse TCRβ clonotypes that associated with mild disease at primary infection. These clonotypes are found at higher frequencies in pre-pandemic repertoires compared to other epitope-specific clonotypes. Longitudinal transcriptomics and TCR analysis, combined with functional evaluation, reveals that the clonotypes persisting 3-4 years post initial infection exhibit distinct functionality compared to those that were lost. Furthermore, spike-specific CD4[SUP]+[/SUP] T cells at this time point show decreased Th1 signatures and enhanced GZMA-driven cytotoxic transcriptomic profiles that were independent of TCR clonotype and associated with viral suppression. In summary, we identify common public TCRs used by immunodominant spike-specific memory CD4[SUP]+[/SUP] T-cells, associated with mild disease outcome, which likely play important protective roles to subsequent viral infection events.


 
Back
Top Bottom